An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions

Not yet recruitingOBSERVATIONAL
Enrollment

1,200

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Chronic Heart Failure With Reduced Ejection FractionWorsening Chronic Heart Failure
Interventions
DRUG

Vericiguat (Verquvo, BAY1021189)

Prescibed as per local label

Trial Locations (1)

Unknown

Many locations, Multiple Locations

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY